Catalog No.
DHB87801
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
Fusion - F9 (coagulation factor 9, coagulation factor IX) recombinant - ALB (albumin, human serum albumin, HSA) 25-609
Applications
Research Grade Biosimilar
Target
Plasma thromboplastin component, F9, Christmas factor, Coagulation factor IX, PTC
Concentration
0.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Ion Exchange Chromatography.
Accession
P00740
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CSL654, Coagulation Factor IX (Recombinant)-Albumin Fusion Protein, F9-ALB, r(FIX)-FP, rFIX-HSA
Clone ID
Albutrepenonacog alfa
Note
For research use only. Not suitable for clinical or therapeutic use.
Pharmacokinetic drug evaluation of albutrepenonacog alfa (CSL654) for the treatment of hemophilia., PMID:27677190
Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion®): A Review of Its Use in Haemophilia B., PMID:27988873
The sudden and unexpected appearance of inhibitors in a previously treated severe haemophilia B patient after the switch to albutrepenonacog alpha., PMID:30088312
Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays., PMID:30418692
Health-related quality of life in paediatric haemophilia B patients treated with rIX-FP., PMID:30427091
Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins., PMID:30520547
Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B., PMID:30866086
Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model., PMID:30992271
Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis., PMID:32333327
High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: Evidence from clinical trials and real-world practice., PMID:32542961
Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain., PMID:33051199
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing., PMID:33460559
Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa., PMID:34225551
In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients., PMID:34651201
External quality assessment for one-stage and chromogenic factor IX assays in samples containing Alprolix (rFIXFc) or Idelvion (rIX-FP) and evidence that UK National External Quality Assessment Scheme for blood coagulation samples are commutable with patient samples., PMID:35040275
Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review., PMID:36132333
Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case Series., PMID:36779089
Successful Multidisciplinary Management of Aortic Valve Repair in Severe Hemophilia B with Extended Half-Life Recombinant Factor IX Concentrate., PMID:36907171
Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa (rIX-FP): A case report., PMID:37323270
Switching and increasing prophylaxis regimen with a genetically recombinant fusion of coagulation factor IX and albumin in haemophilia B: a case report., PMID:37522479
Benefits of rIX-FP prophylaxis in patients with Haemophilia B: real-world evidence from a Spanish reference centre., PMID:37680021
Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B., PMID:38070040
Performance of a Drug-Specific Calibration Curve for Monitoring Treatment With Albutrepenonacog Alfa: A Multicenter Study in Argentina., PMID:40176382
For research use only. Not for human or drug use.
